GelMEDIX
Cambridge, US · Founded 2020 · Delaware corporation · 2 known investors
Biotech
Founders & leadership
MC
Max CotlerExecutive
NA
Nasim AnnabiNamed on SEC filing
RD
Reza DanaNamed on SEC filing
AD
Arthur DriscollNamed on SEC filing
Board
MC
Michael CimaBoard director
PM
Parinaz MotamedyBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$10.1M disclosed across 4 rounds · 2020–2025
▶$747KraisedApr 2026 · 5 investors · BiotechnologyRule 506(b)
▶$747KraisedApr 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Parinaz MotamedyDirector
- Max CotlerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $747K
- Proceeds to insiders
- $40K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedFeb 2025 · 2 investors · BiotechnologyRule 506(b)
▶$1MraisedFeb 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Max CotlerExecutive Officer
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Parinaz MotamedyDirector
- Offering amount
- $4M
- Amount sold
- $1M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.9MraisedMar 2024 · 17 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMar 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Parinaz MotamedyDirector
- Max CotlerExecutive Officer
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Offering amount
- $3.5M
- Amount sold
- $1.9M
- Proceeds to insiders
- $183.3K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6.4MraisedAug 2022 · 4 investors · BiotechnologyRule 506(b)
▶$6.4MraisedAug 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael CimaDirector
- Parinaz MotamedyDirector
- Arthur DriscollExecutive Officer, Director
- Nasim AnnabiDirector
- Reza DanaDirector
- Offering amount
- $8M
- Amount sold
- $6.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapBioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Helix Biomedix3 shared keywordsHelix BioMedix is a publicly traded company (OTCMKTS: HXBM). The stock information page provides investor relations and transfer agent details but does not describe the company's products or business activities.
Evommune3 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
TellBio3 shared keywordsTellBio is a development-stage biotechnology company building the TellDx CTC System, a microfluidic diagnostic platform that isolates and detects circulating tumor cells (CTCs) to detect and monitor cancer progression, along with a therapeutics arm developing anti-cancer drugs based on CTC research. Its CTC isolation technology is exclusively licensed from Massachusetts General Hospital and is deployed as a research tool at centers of excellence.
Contract3 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.
Companies competing with GelMEDIX for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- Who are GelMEDIX's investors?
- GelMEDIX's investors include Beacon Angels, Boston Harbor Angels.
- How much funding has GelMEDIX raised?
- GelMEDIX has disclosed $10.1M raised across 4 rounds.
- Where is GelMEDIX headquartered?
- GelMEDIX is headquartered in Cambridge, US.